KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Change in Account Payables (2016 - 2025)

Amgen has reported Change in Account Payables over the past 17 years, most recently at -$484.0 million for Q4 2025.

  • Quarterly results put Change in Account Payables at -$484.0 million for Q4 2025, down 108.62% from a year ago — trailing twelve months through Dec 2025 was $428.0 million (up 37.18% YoY), and the annual figure for FY2025 was $428.0 million, up 37.18%.
  • Change in Account Payables for Q4 2025 was -$484.0 million at Amgen, down from -$174.0 million in the prior quarter.
  • Over the last five years, Change in Account Payables for AMGN hit a ceiling of $643.0 million in Q2 2024 and a floor of -$484.0 million in Q4 2025.
  • Median Change in Account Payables over the past 5 years was -$74.0 million (2021), compared with a mean of $21.2 million.
  • Biggest five-year swings in Change in Account Payables: plummeted 842.86% in 2021 and later skyrocketed 2060.87% in 2025.
  • Amgen's Change in Account Payables stood at $191.0 million in 2021, then soared by 54.97% to $296.0 million in 2022, then crashed by 163.18% to -$187.0 million in 2023, then dropped by 24.06% to -$232.0 million in 2024, then tumbled by 108.62% to -$484.0 million in 2025.
  • The last three reported values for Change in Account Payables were -$484.0 million (Q4 2025), -$174.0 million (Q3 2025), and $589.0 million (Q2 2025) per Business Quant data.